Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome

Stefan Rentas1, Vinodh Pillai2, Gerald B Wertheim2

  • 1Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Abramson Research Center, Room 716D, 3615 Civic Center Blvd., Philadelphia, PA 19104, United States.

Cancer Genetics
|July 4, 2020
PubMed

Insights

Gain of function variants in SAMD9 cause MIRAGE syndrome, leading to myeloid dysplastic syndrome (MDS). Monitoring leukemia gene mutations tracks MDS to acute myeloid leukemia (AML) progression in these patients.

Area of Science:

  • Genetics
  • Hematology
  • Pediatrics

Background:

  • MIRAGE syndrome, caused by SAMD9 variants, is a rare Mendelian disorder.
  • It presents with myeloid dysplastic syndrome (MDS), immune deficiency, growth restriction, and adrenal insufficiency.
  • Patients often have a significantly reduced lifespan.

Observation:

  • This study details serial bone marrow findings in a 9-year-old patient with MIRAGE syndrome and untreated MDS.
  • Histomorphology revealed progressive hypocellularity with erythroid and megakaryocytic dysplasia.
  • Cytogenetic testing showed monosomy 7, and serial leukemia gene panels detected evolving pre-leukemic clones and mutations in ETV6 and RUNX1.

Findings:

  • The patient developed acute myeloid leukemia (AML) at age 9, driven by sequential mutations.
  • Analysis of 28 patients indicated that MDS presence did not affect overall survival.
  • In silico pathogenicity scores for SAMD9 variants correlated with prognosis.

Implications:

  • Monitoring mutation evolution in leukemia-related genes can track MDS to AML progression in MIRAGE syndrome.
  • Specific SAMD9 mutations likely influence disease severity and patient survival.
  • This research provides insights into the natural history and genetic landscape of MIRAGE syndrome-associated hematologic malignancies.